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CONSERVATIVE TREATMENT IN DIABETES MELLITUS ENDOMETRIAL HYPERPLASIA AND EARLY
ENDOMETRIAL CANCER
Diabetes mellitus and responsiveness of endometrial hyperplasia and early
endometrial cancer to conservative treatment
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ABSTRACT
Objective: The conservative treatment of endometrial hyperplasia without atypia (HWA), atypical endo-
metrial hyperplasia (AH/EIN) and early endometrioid carcinoma (EEC) is based on progestins. We aimed to
assess whether diabetes mellitus affects the responsiveness of HWA, AH/EIN and EEC to conservative
treatment, through a systematic review and meta-analysis.
Study design: Electronic databases were searched for studies assessing the outcome of conservative
treatment in HWA, AH/EIN and EEC, stratified based on the diagnosis of diabetes mellitus. The association
of diabetes mellitus with treatment failure was assessed by using odds ratio (OR). A p-value < .05 was
considered significant. The risk of publication bias was assessed by using a funnel plot. A subgroups anal-
yses was performed based on histologic diagnosis of benignity (HWA) or premalignancy/malignancy
(AH/EIN or EEC).
Results: Six studies with 876 patients (383 HWA, 365 AH/EIN and 128 EEC) were included. Overall,
diabetes mellitus was not associated with outcome of treatment (OR ¼ 1.20; p¼ .62). The association
was not significant in both the HWA subgroup (OR ¼ 0.95; p¼ .93) and in AH/EIN and EEC subgroup (OR
¼ 1.43; p¼ .46). There was no significant risk of publication bias.
Conclusions: Diabetes mellitus does not affect the outcome of conservative treatment in HWA, AH/EIN
and EEC.
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Introduction
Endometrial hyperplasia is an irregular proliferation of endomet-
rial glands, which can be either a benign proliferation, or a neo-
plastic lesion that may evolve into endometrioid carcinoma.
In the 2014 World Health Organization (WHO) classification,
benign endometrial hyperplasia is termed ‘hyperplasia without
atypia’ (HWA), while premalignant hyperplasia is termed ‘atypical
hyperplasia/endometrioid intraepithelial neoplasia’ (AH/EIN). The
diagnosis of HWA or AH/EIN, is based on the presence of cyto-
logic atypia at histologic examination [1–3].
Patients with HWA may be followed without treatment when
asymptomatic; otherwise, progestins are advisable. On the other
hand, total hysterectomy is recommended for AH/EIN. A con-
servative treatment based on progestins can be used in patients
with AH/EIN who desire pregnancy or who are contraindicated
for surgery [4,5]. Such approach may still be chosen in case of
low grade early endometrioid carcinoma limited to the endomet-
rium (EEC) [5,6].
Several meta-analyses have suggested that levonorgestrel-
releasing intrauterine device (LNG-IUD) is safer and more effect-
ive than oral progestins [7–9]. Recently, hysteroscopic resection
followed by progestins has been proposed as an even more
effective conservative treatment [10,11].
Despite the wide use of conservative treatments, a variable
percentage of patients does not respond to progestins, and bear a
considerable risk of progression to myoinvasive disease [12].
Several studies searched for predictive markers of response to
progestins, including clinical, pathologic and immunohistochemi-
cal factors [5,12–15]. However, to date no clinically useful pre-
dictive markers have been identified.
In this review, we focused on diabetes mellitus. Diabetes mel-
litus has been proposed as a risk factor for endometrial cancer
both in the general population and in patients diagnosed with
endometrial hyperplasia [16,17].
The aim of our study was to assess whether diabetes mellitus
affects the responsiveness to conservative treatment in women
with endometrial hyperplasia or EEC.
Materials and methods
Study protocol
Methods for search strategy, study selection, data extraction,
risk of bias assessment and data analysis were designed a pri-
ori. All review stages were conducted independently by two
reviewers (AR, AT). Disagreements were resolved by discussion
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among authors. This study was reported according to the
PRISMA statement [18].
Search strategy
MEDLINE, EMBASE, Web of Sciences, Scopus, ClinicalTrial.gov,
OVID and Cochrane Library as electronic databases were searched
from the inception of each database to June 2018 by using several
different combinations of the following text words: endometrial
hyperplasia; endometrial cancer; endometrioid adenocarcinoma;
endometrial intraepithelial neoplasia; EIN; therapy; treatment; con-
servative; fertility sparing; progestogen; progestin; oral; medroxy-
progesterone; MPA; intrauterine; levonorgestrel; LNG; mirena;
response; regression; resistance; persistence; outcome. Relevant
references of the included articles were also reviewed, and their
abstract were screened.
Study selection
All studies assessing the response to conservative treatment in
women diagnosed with HWA, AH/EIN or EEC were included.
Exclusion criteria were: patients not stratified according to the
diagnosis of diabetes mellitus; case reports; reviews. Language
restrictions were not applied. Studies analyzing data overlapping
with other studies were excluded from the meta-analysis.
Data extraction
Data were extracted from each study without modification and
reported in 2 2 contingency tables. Data extraction was per-
formed according to the PICO. P (Patient, Population, or
Problem) were women diagnosed with HWA, AH/EIN or EEC
and diabetes mellitus, treated conservatively with progestins; I
(Intervention, Prognostic Factor, or Exposure) was the diagnosis
of diabetes mellitus; C (Comparator) were women diagnosed
with HWA, AH/EIN or EEC without diabetes mellitus, treated
conservatively with progestins; O (Outcome) was the response
to conservative treatment.
Diabetes mellitus was defined as a hemoglobin A1c level
6.5%, a fasting plasma glucose level 126mg/dL, or a 2-h
plasma glucose level 200mg/dL [19].
The response to conservative treatment was considered
“good” if the lesion regressed completely, or “poor” if the lesion
persisted or progressed.
Data were also subdivided according to the histologic diagno-
sis into benign (HWA) or premalignant/malignant (AH/EIN
or EEC).
Secondary data extracted were country, period of enrollment,
administration route of progestins (oral vs intrauterine) and
follow-up duration.
Risk of bias within studies assessment
The Methodological Index for Non-Randomized Studies
(MINORS) [20] was used to assess the risk of bias within studies.
For each study, quality criteria were evaluated with regard to
seven domains: (1) Aim (i.e. clearly stated aim); (2) Patients (i.e.
all patients meeting inclusion criteria were included in the study
during the study period); (3) Data (i.e. data were collected
according to a previously established protocol); (4) Endpoint (i.e.
endpoints adequate to the study aim); (5) Bias (i.e. the study
endpoint was assessed without bias); (6) Follow-up (i.e. the
follow-up was sufficiently long to allow the assessment of the
main endpoint), (7) Loss (i.e. no more than 5% of patients were
lost to follow-up). For each domain, authors’ judgment was ‘low
risk’ of bias if the criterion was met, ‘high risk’ if the criterion
was not met, or ‘unclear risk’ if an adequate evaluation of the
criterion was impossible.
Data analysis
The association between diabetes mellitus and responsiveness to
treatment was calculated as odds ratio (OR) for failure of treat-
ment, with 95% confidence interval (CI). OR was calculated for
each study and as pooled estimate, and reported graphically on a
forest plot. A p value< .05 was considered significant.
The inconsistency index (I2) was used to quantify statistical
heterogeneity among studies: heterogeneity was considered min-
imal for I2< 25%, low for I2< 50%, moderate for I2< 75% and
high for I275%. A fixed effect model was adopted in the case
of I2< 50%; otherwise, a random effect model was preferred.
The risk of bias across studies (publication bias) was assessed
by reporting the results on a funnel plot. Asymmetry of funnel
plot indicated a significant risk of publication bias if stronger
association was present in less accurate studies.
Data analysis was performed using Review Manager 5.3
(Copenhagen: The Nordic Cochrane Center, Cochrane
Collaboration, 2014).
Results
Study selection and characteristics
Six studies with a total of 876 patients were included in the sys-
tematic review [21–26]. The whole process of study selection is
reported in Supplementary Figure 1.
The sample assessed included 383 HWA, 365 AH/EIN and
128 EEC. Out of these, 120 AH/EIN were excluded due to the
risk of overlapping data between two studies [25,26], and 3 EEC
were excluded for lack of data in the primary study [26].
Sampling methods included endometrial curettage and hys-
teroscopic biopsy. Regarding administration route of progestins,
640 patients received oral progestins, while 262 patients were
treated by LNG-IUD. The follow-up duration ranged from 1 to
148months. Characteristics of each included studies are reported
in Table 1.
Risk of bias within studies assessment
All studies were considered at low risk of bias for the ‘Aim’,
‘Endpoint’ and ‘Loss’ domains, and at unclear risk for the
‘Data’ domain.
For the ‘Patient’ domain, 3 studies were considered at low
risk and 4 at unclear risk.
For the ‘Bias’ domain, one study was considered at unclear
risk, because the presence of simple hyperplasia on follow-up
was considered as a good response of complex hyperplasia to
treatment; all other studies were considered at low risk instead,
because they considered only a complete absence of hyperplasia
or cancer as a good response to treatment.
For the ‘Follow-up’ domain, 2 studies were considered at
unclear risk, because an unspecified number of patients were fol-
lowed for less than 3months, which should be the minimal time
to ascertain the outcome of treatment [4].
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Authors’ judgments on the risks of bias within studies are
summarized in Supplementary Figure 2.
Meta-analysis
The overall estimate showed an OR of 1.20 (95% CI, 0.58–2.48),
without statistical significance (p¼ .62); statistical heterogeneity
among studies was minimal (I2¼9%).
In the subgroup of AH/EIN and EC, pooled OR was 1.43
(95% CI, 0.55–3.69), without statistical significance (p¼ .46), and
with low heterogeneity among studies (I2¼33%).
In the subgroup of HWA, pooled OR was 0.95 (95% CI,
0.30–2.97), without statistical significance (p¼ .93), and without
heterogeneity among studies (I2¼0%) (Figure 1). The difference
between the subgroups was not statistically significant (p¼ .59)
(Figure 1). The funnel plot showed a symmetrical distribution of
the included studies, hence excluding a significant publication
bias (Figure 2).
Discussion
Main findings and interpretation
Our study showed that diabetes mellitus did not affect the
response to conservative treatment in women with HWA, AH/
EIN or EEC.
The importance of diabetes mellitus in the cancer risk has
long since been subject of debate [27].
In diabetes mellitus type II, insulin-resistance leads to an
increase in the levels of circulating insulin. As a consequence, the
available circulating levels of insulin like growth factor 1 (IGF-1)
also increase. This promotes the activation of pro-proliferative
kinase pathways. Such a mechanism has been proposed as the
cause of the presumed association between diabetes mellitus and
cancer [17,28,29].
With specific regard to endometrial cancer, there have been
several reports of diabetes mellitus as a significant risk factor
[16,30]. However, some authors suggested that the association
between diabetes mellitus and endometrial cancer might be
dependent on BMI. In fact, it is known that increased body fat
correlates to insulin-resistance [31]. By contrast, other studies
suggested that, in diabetic patients, the risk of endometrial can-
cer was constant, independently from BMI [32]. According to a
recent review, while evidence regarding the role of obesity in the
risk of cancer appears robust, the role of diabetes mellitus is less
clear [27].
Other studies have also supported the relevance of diabetes
mellitus as a risk factor for occult cancer in women diagnosed
with endometrial hyperplasia, highlighting its independence form
BMI and proposing its integration in a prognostic algorithm
[17,33,34]. Consistently, a recent meta-analysis showed that dia-
betes mellitus was a risk factor for occult malignancy in women
with endometrial polyps [35].
All these findings call into question whether a diagnosis of
diabetes mellitus may have practical consequences in the man-
agement of patients with endometrial hyperplasia and cancer.
In this meta-analysis, we focused on the conservative treat-
ment based on progestins, which is widely used for endometrial
hyperplasia and cancer, as well as for other endometrial lesions
[36–39]. We found that diabetes mellitus did not significantly
affect the outcome of conservative treatment of endometrial
hyperplasia and EEC.Ta
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We further investigated this association by performing a sub-
group analysis based on histologic diagnosis. In fact, HWA is a
benign condition, while AH/EIN and EEC are neoplastic lesions.
The pathogenetic process of HWA is dysfunctional, hormone-
driven, and caused by an unopposed action of estrogens; on the
other hand, AH/EIN and EEC harbor several mutations that pro-
mote survival and proliferations [40–43].
Although diabetes seemed to have a slightly more negative
effect on AH/EIN and EEC (OR ¼ 1.43) than on HWA (OR ¼
0.95), the results were non-significant in both subgroup; further-
more, also the difference between subgroups was non-significant.
These findings support that diabetic women with endometrial
hyperplasia and cancer are not at higher risk of failure of conser-
vative treatment. Thus, no differences in management and fol-
low-up timing appear to be advisable for diabetic woman with
endometrial hyperplasia and/or cancer conservatively treated.
Such result appears of clinical value, since glycemic control
has been proposed as a possible relevant target in the manage-
ment of women with endometrial hyperplasia and cancer [17,44].
In this regard, a major antidiabetic drug such as metformin has
been considered as a valuable option for the conservative treat-
ment of endometrial hyperplasia and cancer. There is evidence
Figure 1. Forest plots reporting odds ratio (OR) for the association between diabetes mellitus and failure of conservative therapy in patients with endometrial hyper-
plasia without atypia (HWA), atypical hyperplasia (AH/EIN) and early endometrioid carcinoma (EC).
Figure 2. Funnel plot reporting odds ratio (OR) and standard error (SE) for the assessment of the risk of bias across studies.
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that the addition of metformin to progestin may improve the
effectiveness of the conservative treatment; such evidence is also
strengthened by a meta-analysis [45]. However, a further meta-
analysis in this field concluded that scientific evidence did not
support nor contrast with the usefulness of metformin [46].
In this background, we think that our study may provide a
new element to investigate the actual clinical significance of dia-
betes mellitus in women with endometrial hyperplasia and EEC.
Our findings seem to exclude the relevance of diabetes mellitus
in a predictive algorithm of response to conservative treatment
in endometrial hyperplasia and EEC. Further studies are neces-
sary to confirm these results.
Strengths and limitations
To the best of our knowledge, this is the first review and meta-
analysis evaluating the relevance of diabetes mellitus in the con-
servative treatment of endometrial hyperplasia and cancer. We
could assess a quite large sample, analyzing the results separately
for benign functional conditions (HWA) and premalignant/
malignant lesions (AH/EIN and EEC). The low-to-absent statis-
tical heterogeneity among studies and the absence of a significant
risk of publication bias give solidity to our results.
A limitation to our results may be the retrospective design of
the included studies. Another limitation may be the small num-
ber of patients diagnosed with diabetes mellitus, mainly due to
the fact that most patients were premenopausal; in fact, while
young women are more likely to undergo conservative treatment,
they also are less likely to have diabetes.
Finally, it was impossible to assess the results separately for
oral and intrauterine administration of progestins.
Conclusion
Diabetes mellitus does not seem to affect the responsiveness of
HWA, AH/EIN or EEC to progestin-based conservative treat-
ment. Therefore, diabetic patients might be considered for con-
servative treatment without particular concerns and without the
need for a different management or follow-up timing. Further
studies are necessary to confirm these results.
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